NeoGenomics, Inc. Equity Securities, FV-NI, Unrealized Gain (Loss)
NeoGenomics, Inc. (NEO) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $0 for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2022-05-09
- NeoGenomics, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2022-03-31 was $0.00.
- NeoGenomics, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2021-03-31 was -$5.02M.
- NeoGenomics, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2020-03-31 was $0.00.
- NeoGenomics, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2020 was $3.96M.
- NeoGenomics, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2019 was $0.00.
- NeoGenomics, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2018 was $0.00.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|
| 2022-03-31 | $0.00 10-Q · filed 2022-05-09 | |
| 2021-03-31 | -$5.02M 10-Q · filed 2022-05-09 | |
| 2020-12-31 | $3.96M 10-K · filed 2021-02-25 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $0.00 10-K · filed 2021-02-25 | |
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |